Travel Health business demonstrated strong growth of 22%.Additional mpox vaccine orders during outbreak drove higher revenues for the Public Preparedness business and also secured a strong foundation for 2025.Financial guidance for 2025 in line with the Company’s 2024-2027 ambitions. COPENHAGEN, Denmark, February 3, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced preliminary, unaudited financial results for 2024 and provided its financial guidance for 2025. The preliminary revenue in 2024 was DKK 5,7 ...